Pharmacogenetics and pharmacogenomics: Role of mutational analysis in anti-cancer targeted therapy

A. Savonarola, R. Palmirotta, F. Guadagni, F. Silvestris

Research output: Contribution to journalArticlepeer-review

Abstract

The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.

Original languageEnglish
Pages (from-to)277-286
Number of pages10
JournalPharmacogenomics Journal
Volume12
Issue number4
DOIs
Publication statusPublished - Aug 2012

Keywords

  • alcohol dependence
  • CRH
  • GABA
  • glutamate
  • logistic regression
  • neurotransmitter system

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Fingerprint Dive into the research topics of 'Pharmacogenetics and pharmacogenomics: Role of mutational analysis in anti-cancer targeted therapy'. Together they form a unique fingerprint.

Cite this